Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 13/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27288788 | 1.00 | IL1B (0.55) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30718315 | 0.93 | IL1B (0.55) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27288792 | 0.93 | IL1B (0.55) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27289089 | 0.89 | NLRP3 (0.49) | IL1BNLRP3KAT2B | |
| SCHEMBL27289122 | 0.87 | KAT2B (0.46) | IL1BNLRP3KAT2B | |
| SCHEMBL27297428 | 0.87 | IL1B (0.64) | IL1BNLRP3 | |
| SCHEMBL27289128 | 0.87 | KAT2B (0.51) | IL1BNLRP3KAT2B | |
| SCHEMBL27289517 | 0.87 | IL1B (0.54) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26093624 | 0.86 | IL1B (0.74) | IL1BNLRP3 | |
| SCHEMBL27289348 | 0.86 | IL1B (0.58) | IL1BNLRP3CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015357-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NEUMORA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024006559-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015357-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NOD1, CASP1 | IL1B 7/4885NLRP3 1/4885CHRNB2 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.